* Spectrum Pharmaceuticals Inc SPPI.OQ SPPI.O is expected
to show a no change in quarterly revenue when it reports
results on August 12.
* Refinitiv's mean analyst estimate for Spectrum
Pharmaceuticals Inc is for a loss of 25 cents per share. For the
same quarter last year, the company reported a loss of 28 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Spectrum
Pharmaceuticals Inc is $12, about 72.9% above its last closing
price of $3.25.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.30 -0.31 -0.25 Beat 20.6
Dec. 31 2020 -0.29 -0.29 Met 0
Sep. 30 2020 -0.35 -0.35 -0.37 Missed -5.7
Jun. 30 2020 -0.29 -0.32 -0.28 Beat 11.4
Mar. -0.34 -0.35 -0.36 Missed -4
31 2020
Dec. 31 2019 -0.33 -0.33 -0.35 Missed -7.4
Sep. 30 2019 -0.36 -0.41 -0.23 Beat 44.6
Jun. 30 2019 -0.32 -0.27 -0.23 Beat 16.1
This summary was machine generated August 6 at 14:32 GMT. All
figures in US dollars unless otherwise stated